Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-Cancer Drug Market 2018, Forecast to 2023

  • receipt Report ID : 138306
  • calendar_today Published On: Jan, 2019
  • file_copy Pages: 151
  • list Pharmaceuticals and Healthcare

Anticancer drug, also called antineoplastic drug, any drug that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones.

Scope of the Report:

This report focuses on the Anti-Cancer Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

China and India are expected to offer good opportunities an account of improvement in healthcare infrastructure. In Africa, industry is expected to drive at lower rate on account of lack of healthcare infrastructure, expensive medical services and lack of consumer awareness.

Central & South America is expected to drive at stable rates on account of costly medicines coupled with minimal awareness initiatives by regional government. Global market is also expected to have legal conflicts arising on account of patents which in turn are expected to negatively impact overall industry.

The worldwide market for Anti-Cancer Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers

Merck

Bristol-Myers Squibb

Bayer

GlaxoSmithKline

Novartis

Sanofi

Pfizer

Amgen

Celgene Corporation

Ariad Pharmaceuticals

Eli Lilly

Hoffmann-La Roche Ltd.

AstraZeneca

Boehringer Ingelheim GmbH

Teva Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Avastin

Rituxan

Herceptin

Alimta

Market Segment by Applications, can be divided into

Hospital

Clinic

Home Care

There are 15 Chapters to deeply display the global Anti-Cancer Drug market.

Chapter 1, to describe Anti-Cancer Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Anti-Cancer Drug, with sales, revenue, and price of Anti-Cancer Drug, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Cancer Drug, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Anti-Cancer Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Anti-Cancer Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Anti-Cancer Drug Introduction

1.2 Market Analysis by Type

1.2.1 Avastin

1.2.2 Rituxan

1.2.3 Herceptin

1.2.4 Alimta

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinic

1.3.3 Home Care

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Merck

2.1.1 Business Overview

2.1.1.1 Merck Description

2.1.1.2 Merck Headquarter, Main Business and Finance Overview

2.1.2 Merck Anti-Cancer Drug Product Introduction

2.1.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.1.2.2 Anti-Cancer Drug Product Information

2.1.3 Merck Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.1 Merck Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.2 Global Merck Anti-Cancer Drug Market Share in 2017

2.2 Bristol-Myers Squibb

2.2.1 Business Overview

2.2.1.1 Bristol-Myers Squibb Description

2.2.1.2 Bristol-Myers Squibb Headquarter, Main Business and Finance Overview

2.2.2 Bristol-Myers Squibb Anti-Cancer Drug Product Introduction

2.2.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.2.2.2 Anti-Cancer Drug Product Information

2.2.3 Bristol-Myers Squibb Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.1 Bristol-Myers Squibb Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.2 Global Bristol-Myers Squibb Anti-Cancer Drug Market Share in 2017

2.3 Bayer

2.3.1 Business Overview

2.3.1.1 Bayer Description

2.3.1.2 Bayer Headquarter, Main Business and Finance Overview

2.3.2 Bayer Anti-Cancer Drug Product Introduction

2.3.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.3.2.2 Anti-Cancer Drug Product Information

2.3.3 Bayer Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.1 Bayer Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.2 Global Bayer Anti-Cancer Drug Market Share in 2017

2.4 GlaxoSmithKline

2.4.1 Business Overview

2.4.1.1 GlaxoSmithKline Description

2.4.1.2 GlaxoSmithKline Headquarter, Main Business and Finance Overview

2.4.2 GlaxoSmithKline Anti-Cancer Drug Product Introduction

2.4.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.4.2.2 Anti-Cancer Drug Product Information

2.4.3 GlaxoSmithKline Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.1 GlaxoSmithKline Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.2 Global GlaxoSmithKline Anti-Cancer Drug Market Share in 2017

2.5 Novartis

2.5.1 Business Overview

2.5.1.1 Novartis Description

2.5.1.2 Novartis Headquarter, Main Business and Finance Overview

2.5.2 Novartis Anti-Cancer Drug Product Introduction

2.5.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.5.2.2 Anti-Cancer Drug Product Information

2.5.3 Novartis Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.1 Novartis Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.2 Global Novartis Anti-Cancer Drug Market Share in 2017

2.6 Sanofi

2.6.1 Business Overview

2.6.1.1 Sanofi Description

2.6.1.2 Sanofi Headquarter, Main Business and Finance Overview

2.6.2 Sanofi Anti-Cancer Drug Product Introduction

2.6.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.6.2.2 Anti-Cancer Drug Product Information

2.6.3 Sanofi Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6.3.1 Sanofi Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6.3.2 Global Sanofi Anti-Cancer Drug Market Share in 2017

2.7 Pfizer

2.7.1 Business Overview

2.7.1.1 Pfizer Description

2.7.1.2 Pfizer Headquarter, Main Business and Finance Overview

2.7.2 Pfizer Anti-Cancer Drug Product Introduction

2.7.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.7.2.2 Anti-Cancer Drug Product Information

2.7.3 Pfizer Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7.3.1 Pfizer Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7.3.2 Global Pfizer Anti-Cancer Drug Market Share in 2017

2.8 Amgen

2.8.1 Business Overview

2.8.1.1 Amgen Description

2.8.1.2 Amgen Headquarter, Main Business and Finance Overview

2.8.2 Amgen Anti-Cancer Drug Product Introduction

2.8.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.8.2.2 Anti-Cancer Drug Product Information

2.8.3 Amgen Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8.3.1 Amgen Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8.3.2 Global Amgen Anti-Cancer Drug Market Share in 2017

2.9 Celgene Corporation

2.9.1 Business Overview

2.9.1.1 Celgene Corporation Description

2.9.1.2 Celgene Corporation Headquarter, Main Business and Finance Overview

2.9.2 Celgene Corporation Anti-Cancer Drug Product Introduction

2.9.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.9.2.2 Anti-Cancer Drug Product Information

2.9.3 Celgene Corporation Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9.3.1 Celgene Corporation Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9.3.2 Global Celgene Corporation Anti-Cancer Drug Market Share in 2017

2.10 Ariad Pharmaceuticals

2.10.1 Business Overview

2.10.1.1 Ariad Pharmaceuticals Description

2.10.1.2 Ariad Pharmaceuticals Headquarter, Main Business and Finance Overview

2.10.2 Ariad Pharmaceuticals Anti-Cancer Drug Product Introduction

2.10.2.1 Anti-Cancer Drug Production Bases, Sales Regions and Major Competitors

2.10.2.2 Anti-Cancer Drug Product Information

2.10.3 Ariad Pharmaceuticals Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10.3.1 Ariad Pharmaceuticals Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10.3.2 Global Ariad Pharmaceuticals Anti-Cancer Drug Market Share in 2017

2.11 Eli Lilly

2.11.1 Business Overview

2.11.2 Eli Lilly Anti-Cancer Drug Product Introduction

2.11.3 Eli Lilly Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.12 Hoffmann-La Roche Ltd.

2.12.1 Business Overview

2.12.2 Hoffmann-La Roche Ltd. Anti-Cancer Drug Product Introduction

2.12.3 Hoffmann-La Roche Ltd. Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.13 AstraZeneca

2.13.1 Business Overview

2.13.2 AstraZeneca Anti-Cancer Drug Product Introduction

2.13.3 AstraZeneca Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.14 Boehringer Ingelheim GmbH

2.14.1 Business Overview

2.14.2 Boehringer Ingelheim GmbH Anti-Cancer Drug Product Introduction

2.14.3 Boehringer Ingelheim GmbH Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.15 Teva Pharmaceuticals

2.15.1 Business Overview

2.15.2 Teva Pharmaceuticals Anti-Cancer Drug Product Introduction

2.15.3 Teva Pharmaceuticals Anti-Cancer Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Anti-Cancer Drug Market Competition, by Manufacturer

3.1 Global Anti-Cancer Drug Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Anti-Cancer Drug Revenue and Market Share by Manufacturer (2016-2017)

3.3 Global Anti-Cancer Drug Price by Manufacturer (2016-2017)

3.4 Market Concentration Rate

3.4.1 Top 3 Anti-Cancer Drug Manufacturer Market Share in 2017

3.4.2 Top 5 Anti-Cancer Drug Manufacturer Market Share in 2017

3.5 Market Competition Trend

4 Global Anti-Cancer Drug Market Analysis by Regions

4.1 Global Anti-Cancer Drug Sales, Revenue and Market Share by Regions

4.1.1 Global Anti-Cancer Drug Sales by Regions (2013-2018)

4.1.2 Global Anti-Cancer Drug Revenue by Regions (2013-2018)

4.2 North America Anti-Cancer Drug Sales, Revenue and Growth Rate (2013-2018)

4.3 Europe Anti-Cancer Drug Sales, Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Anti-Cancer Drug Sales, Revenue and Growth Rate (2013-2018)

4.5 South America Anti-Cancer Drug Sales, Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Anti-Cancer Drug Sales, Revenue and Growth Rate (2013-2018)

5 North America Anti-Cancer Drug by Countries, Type, Application and Manufacturers

5.1 North America Anti-Cancer Drug Sales, Revenue and Market Share by Countries

5.1.1 North America Anti-Cancer Drug Sales by Countries (2013-2018)

5.1.2 North America Anti-Cancer Drug Revenue by Countries (2013-2018)

5.1.3 United States Anti-Cancer Drug Sales and Growth Rate (2013-2018)

5.1.4 Canada Anti-Cancer Drug Sales and Growth Rate (2013-2018)

5.1.5 Mexico Anti-Cancer Drug Sales and Growth Rate (2013-2018)

5.2 North America Anti-Cancer Drug Sales and Revenue (Value) by Manufacturers (2016-2017)

5.2.1 North America Anti-Cancer Drug Sales by Manufacturers (2016-2017)

5.2.2 North America Anti-Cancer Drug Revenue by Manufacturers (2016-2017)

5.3 North America Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

5.3.1 North America Anti-Cancer Drug Sales and Sales Share by Type (2013-2018)

5.3.2 North America Anti-Cancer Drug Revenue and Revenue Share by Type (2013-2018)

5.4 North America Anti-Cancer Drug Sales, Revenue and Market Share by Application (2013-2018)

5.4.1 North America Anti-Cancer Drug Sales and Sales Share by Application (2013-2018)

5.4.2 North America Anti-Cancer Drug Revenue and Revenue Share by Application (2013-2018)

6 Europe Anti-Cancer Drug by Countries, Type, Application and Manufacturers

6.1 Europe Anti-Cancer Drug Sales, Revenue and Market Share by Countries

6.1.1 Europe Anti-Cancer Drug Sales by Countries (2013-2018)

6.1.2 Europe Anti-Cancer Drug Revenue by Countries (2013-2018)

6.1.3 Germany Anti-Cancer Drug Sales and Growth Rate (2013-2018)

6.1.4 UK Anti-Cancer Drug Sales and Growth Rate (2013-2018)

6.1.5 France Anti-Cancer Drug Sales and Growth Rate (2013-2018)

6.1.6 Russia Anti-Cancer Drug Sales and Growth Rate (2013-2018)

6.1.7 Italy Anti-Cancer Drug Sales and Growth Rate (2013-2018)

6.2 Europe Anti-Cancer Drug Sales and Revenue (Value) by Manufacturers (2016-2017)

6.2.1 Europe Anti-Cancer Drug Sales by Manufacturers (2016-2017)

6.2.2 Europe Anti-Cancer Drug Revenue by Manufacturers (2016-2017)

6.3 Europe Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

6.3.1 Europe Anti-Cancer Drug Sales and Sales Share by Type (2013-2018)

6.3.2 Europe Anti-Cancer Drug Revenue and Revenue Share by Type (2013-2018)

6.4 Europe Anti-Cancer Drug Sales, Revenue and Market Share by Application (2013-2018)

6.4.1 Europe Anti-Cancer Drug Sales and Sales Share by Application (2013-2018)

6.4.2 Europe Anti-Cancer Drug Revenue and Revenue Share by Application (2013-2018)

7 Asia-Pacific Anti-Cancer Drug by Countries, Type, Application and Manufacturers

7.1 Asia-Pacific Anti-Cancer Drug Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Anti-Cancer Drug Sales by Countries (2013-2018)

7.1.2 Asia-Pacific Anti-Cancer Drug Revenue by Countries (2013-2018)

7.1.3 China Anti-Cancer Drug Sales and Growth Rate (2013-2018)

7.1.4 Japan Anti-Cancer Drug Sales and Growth Rate (2013-2018)

7.1.5 Korea Anti-Cancer Drug Sales and Growth Rate (2013-2018)

7.1.6 India Anti-Cancer Drug Sales and Growth Rate (2013-2018)

7.1.7 Southeast Asia Anti-Cancer Drug Sales and Growth Rate (2013-2018)

7.2 Asia-Pacific Anti-Cancer Drug Sales and Revenue (Value) by Manufacturers (2016-2017)

7.2.1 Asia-Pacific Anti-Cancer Drug Sales by Manufacturers (2016-2017)

7.2.2 Asia-Pacific Anti-Cancer Drug Revenue by Manufacturers (2016-2017)

7.3 Asia-Pacific Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

7.3.1 Asia-Pacific Anti-Cancer Drug Sales and Sales Share by Type (2013-2018)

7.3.2 Asia-Pacific Anti-Cancer Drug Revenue and Revenue Share by Type (2013-2018)

7.4 Asia-Pacific Anti-Cancer Drug Sales, Revenue and Market Share by Application (2013-2018)

7.4.1 Asia-Pacific Anti-Cancer Drug Sales and Sales Share by Application (2013-2018)

7.4.2 Asia-Pacific Anti-Cancer Drug Revenue and Revenue Share by Application (2013-2018)

8 South America Anti-Cancer Drug by Countries, Type, Application and Manufacturers

8.1 South America Anti-Cancer Drug Sales, Revenue and Market Share by Countries

8.1.1 South America Anti-Cancer Drug Sales by Countries (2013-2018)

8.1.2 South America Anti-Cancer Drug Revenue by Countries (2013-2018)

8.1.3 Brazil Anti-Cancer Drug Sales and Growth Rate (2013-2018)

8.1.4 Argentina Anti-Cancer Drug Sales and Growth Rate (2013-2018)

8.1.5 Colombia Anti-Cancer Drug Sales and Growth Rate (2013-2018)

8.2 South America Anti-Cancer Drug Sales and Revenue (Value) by Manufacturers (2016-2017)

8.2.1 South America Anti-Cancer Drug Sales by Manufacturers (2016-2017)

8.2.2 South America Anti-Cancer Drug Revenue by Manufacturers (2016-2017)

8.3 South America Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

8.3.1 South America Anti-Cancer Drug Sales and Sales Share by Type (2013-2018)

8.3.2 South America Anti-Cancer Drug Revenue and Revenue Share by Type (2013-2018)

8.4 South America Anti-Cancer Drug Sales, Revenue and Market Share by Application (2013-2018)

8.4.1 South America Anti-Cancer Drug Sales and Sales Share by Application (2013-2018)

8.4.2 South America Anti-Cancer Drug Revenue and Revenue Share by Application (2013-2018)

9 Middle East and Africa Anti-Cancer Drug by Countries, Type, Application and Manufacturers

9.1 Middle East and Africa Anti-Cancer Drug Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Anti-Cancer Drug Sales by Countries (2013-2018)

9.1.2 Middle East and Africa Anti-Cancer Drug Revenue by Countries (2013-2018)

9.1.3 Saudi Arabia Anti-Cancer Drug Sales and Growth Rate (2013-2018)

9.1.4 UAE Anti-Cancer Drug Sales and Growth Rate (2013-2018)

9.1.5 Egypt Anti-Cancer Drug Sales and Growth Rate (2013-2018)

9.1.6 Nigeria Anti-Cancer Drug Sales and Growth Rate (2013-2018)

9.1.7 South Africa Anti-Cancer Drug Sales and Growth Rate (2013-2018)

9.2 Middle East and Africa Anti-Cancer Drug Sales and Revenue (Value) by Manufacturers (2016-2017)

9.2.1 Middle East and Africa Anti-Cancer Drug Sales by Manufacturers (2016-2017)

9.2.2 Middle East and Africa Anti-Cancer Drug Revenue by Manufacturers (2016-2017)

9.3 Middle East and Africa Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

9.3.1 Middle East and Africa Anti-Cancer Drug Sales and Sales Share by Type (2013-2018)

9.3.1 Middle East and Africa Anti-Cancer Drug Revenue and Revenue Share by Type (2013-2018)

9.4 Middle East and Africa Anti-Cancer Drug Sales, Revenue and Market Share by Application (2013-2018)

9.4.1 Middle East and Africa Anti-Cancer Drug Sales and Sales Share by Application (2013-2018)

9.4.2 Middle East and Africa Anti-Cancer Drug Revenue and Revenue Share by Application (2013-2018)

10 Global Anti-Cancer Drug Market Segment by Type

10.1 Global Anti-Cancer Drug Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Anti-Cancer Drug Sales and Market Share by Type (2013-2018)

10.1.2 Global Anti-Cancer Drug Revenue and Market Share by Type (2013-2018)

10.2 Avastin Sales Growth and Price

10.2.1 Global Avastin Sales Growth (2013-2018)

10.2.2 Global Avastin Price (2013-2018)

10.3 Rituxan Sales Growth and Price

10.3.1 Global Rituxan Sales Growth (2013-2018)

10.3.2 Global Rituxan Price (2013-2018)

10.4 Herceptin Sales Growth and Price

10.4.1 Global Herceptin Sales Growth (2013-2018)

10.4.2 Global Herceptin Price (2013-2018)

10.5 Alimta Sales Growth and Price

10.5.1 Global Alimta Sales Growth (2013-2018)

10.5.2 Global Alimta Price (2013-2018)

11 Global Anti-Cancer Drug Market Segment by Application

11.1 Global Anti-Cancer Drug Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinic Sales Growth (2013-2018)

11.4 Home Care Sales Growth (2013-2018)

12 Anti-Cancer Drug Market Forecast (2018-2023)

12.1 Global Anti-Cancer Drug Sales, Revenue and Growth Rate (2018-2023)

12.2 Anti-Cancer Drug Market Forecast by Regions (2018-2023)

12.2.1 North America Anti-Cancer Drug Market Forecast (2018-2023)

12.2.2 Europe Anti-Cancer Drug Market Forecast (2018-2023)

12.2.3 Asia-Pacific Anti-Cancer Drug Market Forecast (2018-2023)

12.2.4 South America Anti-Cancer Drug Market Forecast (2018-2023)

12.2.5 Middle East and Africa Anti-Cancer Drug Market Forecast (2018-2023)

12.3 Anti-Cancer Drug Market Forecast by Type (2018-2023)

12.3.1 Global Anti-Cancer Drug Sales Forecast by Type (2018-2023)

12.3.2 Global Anti-Cancer Drug Market Share Forecast by Type (2018-2023)

12.4 Anti-Cancer Drug Market Forecast by Application (2018-2023)

12.4.1 Global Anti-Cancer Drug Sales Forecast by Application (2018-2023)

12.4.2 Global Anti-Cancer Drug Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Anti-Cancer Drug Picture

Table Product Specifications of Anti-Cancer Drug

Figure Global Anti-Cancer Drug CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD M

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery